Li et al. [40] examined the post-chemotherapeutic CD44+/CD24− BCSC subpopulation in 31 BC patients with HER2− tumor who received docetaxel or doxorubicin and cyclophosphamide for 12 weeks at standard doses (group 1) and in 21 patients with locally advanced HER2+ BC who received lapatinib for 6 weeks followed by docetaxel and trastuzumab for 12 weeks at standard doses (group 2). This evidence concerns the gene CD44 and breast cancer.